Hangzhou Hekang Pharmaceutical Co., Ltd.
地址：(Intersection of No. 18 Street and No. 1 Street) No. 101, No.1 Street, Economic Development Zone, Hangzhou City, Zhejiang, China
Switchboard:+86-571-86709999
Fax:+86-571-86708558
P. C.: 310018
URL:www.hekangpharm.com
Pregabalin capsules (approval number: National medical permit No. H20130064, National medical permit No. H20130065, National medical permit No. H20130073)
The product obtained registration approval on June 26, 2013. Specifications: 25mg, 75mg, and 100mg. Indications: add-on therapy of complex partial epileptic attack of adults.
FDA specification states that pregabalin capsules can be used in the treatment of (1) neuralgia related to diabetic peripheral neuropathy (DPN); (2) postherpetic neuralgia (PHN); (3) add-on therapy of complex partial epileptic attack of adults; (4) fibromyalgia; (5) neuralgia related to spinal cord injury. The product can be used in generalized anxiety disorder in European Union.